Less than 3 weeks ago, BHP Group Ltd (ASX: BHP) shares were trading at record highs.

Now they’re heading the other way.

The mining giant is down another 1.13% to $60.18 on Monday morning, extending a sell-off that started late last week.

BHP closed at $64.58 last Wednesday, so the stock has dropped around 6.8% in just 3 trading sessions.

Friday did most of the damage, with the shares dropping 4.05% as mining shares were hit by uncertainty around US copper tariffs.

After such a quick pullback, some investors may be wondering whether BHP is starting to look cheap again.

I’m not sure we’re there yet.

The rally has still been huge

The first thing I’d like to point out is just how far BHP shares have already run.

Even after the recent fall, the stock is still up around 33% in 2026.

It is now about 13% below its 52-week high of $68.77, reached in late August.

So, while the 6.8% drop looks significant, BHP is coming off a very strong run.

The business itself has also been performing well.

FY26 revenue increased 15% to US$58.8 billion, while underlying EBITDA rose 27% to US$32.9 billion. Net debt fell to US$8.7 billion, and the full-year dividend increased to 172 US cents per share.

Copper has become a large part of the business, generating around 54% of underlying EBITDA last year.

Is BHP actually cheap?

This is where I think things get more interesting.

The average 12-month broker price target tracked by TipRanks is $59.23, around 2% below today’s share price.

Of the 15 analysts shown, 13 have a hold rating, with only 1 buy and 1 sell.

There’s also a wide range of views. Morgan Stanley has a $68 target, while Freedom Capital Markets is at $66. Jefferies and Bank of America are both sitting at $65.

At the other end, Bernstein has a $44 target.

Would I buy after the fall?

I can see why investors might be tempted to buy after the latest decline.

BHP is still a very profitable business, and its growing exposure to copper gives investors another reason to stay interested.

But there are still a few things to watch, including softer iron ore prices and ongoing labour negotiations at Port Hedland.

At $60.18, I think BHP looks more attractive than it did near $69.

With broker targets clustered close to the current price, I’d still want BHP to fall a little further before buying.

The post Down almost 7% in 3 days, are BHP shares finally good value? appeared first on The Motley Fool Australia.

More reading

• Are ASX shares heading for a crash? Here’s how I’m preparing
• Down almost 10%! Why are ASX copper shares tanking?
• Iron ore is back below US$100. Are BHP and Rio Tinto shares still buys?
• ASX 200 dives to a 6-week low. What’s behind today’s sell-off?
• Up 62% in a year are BHP shares now a buy, hold or sell?

Bank of America is an advertising partner of Motley Fool Money. Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Jefferies Financial Group. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

“Could the next financial crisis already be sitting inside your superannuation account?” Wealth Within chief analyst and founder Dale Gillham posited over the weekend.

“It sounds alarmist, but regulators are increasingly asking it as Australia’s private credit market has grown to around $250 billion,” he added.

That compares to Australia’s total super assets of around $4.4 trillion.

What new crisis is brewing for superannuation accounts?

The crisis Gillham is talking about is the recent collapse of residential property developer Bathla Group.

Amid slumping property sales, high interest rates, and rising labour and material costs, Bathla entered into voluntary administration in August. The company has around $3.4 billion in liabilities, which are largely held by private credit lenders.

Gillham said the collapse has exposed dangerous cracks in Australia’s private credit market, putting millions of superannuation accounts at risk amid ongoing elevated interest rates.

The level of that risk will depend, to some extent, on how soon you plan to retire, and in which asset classes you’ve invested your superannuation.

“ASIC has repeatedly highlighted the growing connection between private credit and the super sector, warning investors to better understand the risks involved,” Gillham said.

He noted:

What was once a niche corner of finance has become one of the country’s fastest-growing sources of funding. Most Australians have probably never heard of private credit. Yet many could already have exposure through their superannuation.

The bigger picture

Gillham said that Bathla’s collapse wasn’t the real story behind the growing risk to millions of superannuation accounts. However, the property developer’s insolvency had “thrust those risks into the spotlight”.

He said, “The real issue is that many of the conditions that could place pressure on private credit are already emerging.”

Gillham explained:

Interest rates remain elevated, inflation has proven more persistent than many expected, construction costs remain significantly higher than before the pandemic and parts of the property market are beginning to soften.

At the same time, developers who borrowed heavily during years of ultra-low interest rates are being forced to refinance at much higher borrowing costs.

Which would seem to make Bathla a bit of a canary in a coal mine situation.

Indeed, Gillham noted, “Pressure then begins to build across the entire system, and that is where the risk to superannuation begins.”

He added:

If several major developers fail within a short period, fund managers may be forced to write down the value of their loans. Those write-downs could then trigger redemption requests from investors seeking to reduce their exposure.

Gillham concluded, “The real risk is that Bathla won’t be remembered as an isolated collapse, but as the first domino to fall.”

The post Did this $3.4 billion Black Swan event just put your superannuation at risk? appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug
• Cleanaway Waste Management provides EQT bid update
• By September 2027, Wesfarmers shares could turn $10,000 into…
• Forget Nvidia. This little-known ETF is up more than 3,600% in 2026
• 2 ASX shares tipped to grow 30% or more in the next 12 months

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced its brain cancer imaging drug, Pixclara, has won approval from the US FDA—making it the first FET-PET imaging drug cleared for use in glioma and expanding Telix’s precision medicine portfolio.

What did Telix Pharmaceuticals report?

• FDA approved Pixclara® (floretyrosine F 18), for imaging gliomas (brain cancer) in adult and paediatric patients
• Pixclara is the first FDA-approved FET-PET imaging drug for glioma
• Pixclara’s approval addresses a significant unmet need in US brain cancer diagnostics
• Product expansion reinforces Telix’s position in precision diagnostics and targeted radiopharmaceutical “theranostics”

What else do investors need to know?

Pixclara is the only FDA-approved radiopharmaceutical imaging drug specifically for glioma, a difficult-to-treat brain cancer representing around 24,000 new cases annually in the US. The new drug is indicated for adults and children as young as one month old and is expected to support better treatment decision-making for both clinicians and patients.

The approval also makes Pixclara eligible for widespread clinical use. FET-PET imaging has been recommended in various international guidelines, but until now, there was no FDA-approved product available in the United States. Telix already has other FDA-approved imaging offerings and is working on advancing late-stage therapies across multiple cancers.

What did Telix Pharmaceuticals management say?

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said:

FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.

What’s next for Telix Pharmaceuticals?

Telix says Pixclara is already the subject of a Phase 3 trial for diagnosis in additional brain conditions, with potential expansion to brain metastases. The company continues to leverage its global diagnostics platform and late-stage radiopharmaceutical pipeline to target market leadership in both imaging and treatment for several high-need cancers.

Telix’s broader pipeline includes late-stage assets in prostate, kidney, and glioblastoma cancers, with a focus on bringing further precision medicine products to both existing and new markets worldwide.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 12%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• CSL led the ASX healthcare shares rebound. Can it continue?
• 4 high conviction ASX stock picks from Canaccord Genuity
• Telix shares are up 98%: Is there more upside to come?
• Telix shares are tumbling. Is the stock finally at fair value?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.